40 Years of Duocarmycins: A Graphical Structure/Function Review of Their Chemical Evolution, from SAR to Prodrugs and ADCs (vol 2, pg 2636, 2022)

In the Introduction and in section 3.3 of the original article, we mistakenly referred to the ADC SYD985 as having been recently FDA-approved. Instead, we should have specified that it was recently granted FDA Fast Track designation (after positive results from a Phase I study with pretreated last-line HER2-positive metastatic breast cancer patients; SYD985.001/ NCT02277717; 2018);1 and that following positive results of a BV had filed the Biologics License Application (BLA) for the use of SYD985 in patients with HER2-positive unresectable locally advanced or metastatic breast cancer at the FDA in July 2022, with an expected decision date at May 12, 2023 All reported results, statistics, and conclusions of the paper remain unchanged.